As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
A newly published cache of CRLs includes six novel oncology drugs.
The deal for ISB 2001 is worth $700m up front.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
ESO-T01 delivers its first four multiple myeloma case reports.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
